Advertisement

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Opening Session Panel Discussion

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Advertisement

Advertisement

Oct

11

Today In Oncology

HER2-Positive Breast Cancer FDA Approves Triplet for Maintenance Therapy

FDA Approves Belzutifan in Combination With Lenvatinib for Advanced ccRCC

FDA Approves Atezolizumab in Combination With Chemotherapy for Stage III dMMR Colon Cancer

Cancer Statistics 2026: Incidence, Mortality, Survival, and Disparities in U.S. Oncology

FDA Approves First-Line Pirtobrutinib for CLL-SLL

Advertisement

© 2026 HSP News Service, L.L.C.